在阿尔茨海默病中揭示生物标志物检测:微阵列分析的计算方法
Noor Saba Khan1, Saumya Choudhary1, Mohd Ali2
1Biomedical Informatics Centre, ICMR-National Institute of Pathology, New Delhi, 110029 India.
3 Biotech
|November 28, 2024
概括
研究人员确定了参与阿尔茨海默病 (AD) 的关键基因和途径. 这一发现为治疗这种神经退行性疾病提供了潜在的新生物标志物和治疗点.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种流行的神经退行性疾病,具有复杂的分子基础.
- 了解AD的分子机制对于开发有效的生物标志物和治疗方法至关重要.
研究的目的:
- 在阿尔茨海默病中识别差异表达基因 (DEGs).
- 探索这些DEGs,代谢途径和其他神经系统疾病之间的联系.
- 为AD建立一个蛋白质与蛋白质相互作用 (PPI) 网络.
主要方法:
- 对基因表达特征GSE5281 (161个样本:87个AD,74个对照) 的分析.
- 对于DEGs的路径分析进行KEGG查.
- 蛋白与蛋白相互作用 (PPI) 网络和模块分析以确定枢纽基因.
主要成果:
- 鉴定了包括ACTB,EGFR,GAPDH,MAPK1和SNAP25在内的枢纽基因.
- 与AD病理学相关的失调基因,包括改变的核酸代谢和血脑屏障 (BBB) 功能障碍.
- 揭示了与骨质疏松症和微管稳定性的潜在联系.
结论:
- 已识别的枢纽基因和通路代表了AD的潜在预测生物标志物.
- 这些发现可能引导开发阿尔茨海默病的新疗法和预防策略.
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
DNA Microarrays
17.2K
Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
17.2K


